H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Paratek Pharmaceuticals to $10 from $20 and keeps a Buy rating on the shares post the Q4 results.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRTK:
- Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million
- Paratek Pharmaceuticals sees FY23 revenue $143M-$158M, consensus $232.02M
- Paratek Pharmaceuticals reports Q4 EPS (13c), consensus 9c
- Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16
- Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)